Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing
- PMID: 15883175
- DOI: 10.1093/jac/dki146
Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing
Abstract
Objectives: To investigate the variability in antimicrobial susceptibility of Pseudomonas aeruginosa from sputa of patients with cystic fibrosis, to compare testing individual colonies of the same morphotype either separately or combined and to study the reproducibility of testing antimicrobial susceptibility within and between laboratories.
Methods: One hundred and one sputa were cultured. Four colonies of each P. aeruginosa morphotype were suspended. Susceptibility to 12 agents by disc diffusion was tested individually or by pooling the four suspensions. A sputum sample containing four morphotypes of one genotype of P. aeruginosa was used to study reproducibility. Susceptibility was tested in duplicate by eight biomedical scientists in one laboratory and by routine procedures in seven different laboratories.
Results: There was a mean of four morphotypes of P. aeruginosa per sputum and three antibiograms per morphotype. In some cases, all four colonies of a single morphotype had different antibiograms. The susceptibility profiles of single isolates of P. aeruginosa correlated poorly with pooled cultures, with the pooled tests missing resistance. Results from one sample tested in duplicate by eight biomedical scientists in one laboratory and in seven other laboratories did not correlate well. The wide range of zone sizes in disc diffusion tests illustrated the variation in susceptibility of 48 colonies from one sputum sample.
Conclusions: The role of conventional antimicrobial susceptibility testing is questionable once P. aeruginosa chronically infects the cystic fibrosis lung. A range of susceptibility patterns is seen, even within a morphotype. Routine test results are not reproducible and underestimate resistance.
Similar articles
-
Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.J Antimicrob Chemother. 2009 Apr;63(4):728-32. doi: 10.1093/jac/dkp007. Epub 2009 Feb 4. J Antimicrob Chemother. 2009. PMID: 19193658
-
Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media.J Antimicrob Chemother. 2008 May;61(5):1057-61. doi: 10.1093/jac/dkn081. Epub 2008 Mar 3. J Antimicrob Chemother. 2008. PMID: 18316821
-
Pseudomonas aeruginosa from cystic fibrosis patients: study using whole cell RAPD and antibiotic susceptibility.Pathol Biol (Paris). 1998 May;46(5):319-24. Pathol Biol (Paris). 1998. PMID: 9769892
-
Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.Paediatr Respir Rev. 2007 Sep;8(3):249-55. doi: 10.1016/j.prrv.2007.04.006. Epub 2007 Jun 5. Paediatr Respir Rev. 2007. PMID: 17868923 Review.
-
[Evaluation of multiple Pseudomonas aeruginosa strains with different characteristics in clinical specimens; combined results from serotyping, drug susceptibility and enzyme production].Rinsho Byori. 1995 Nov;43(11):1135-9. Rinsho Byori. 1995. PMID: 8551677 Review. Japanese.
Cited by
-
Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa.J Clin Microbiol. 2008 Oct;46(10):3491-3. doi: 10.1128/JCM.00357-08. Epub 2008 Aug 6. J Clin Microbiol. 2008. PMID: 18685006 Free PMC article.
-
Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis.PLoS One. 2015 Dec 3;10(12):e0144022. doi: 10.1371/journal.pone.0144022. eCollection 2015. PLoS One. 2015. PMID: 26633539 Free PMC article.
-
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.Cochrane Database Syst Rev. 2017 Oct 5;10(10):CD009528. doi: 10.1002/14651858.CD009528.pub4. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jun 10;6:CD009528. doi: 10.1002/14651858.CD009528.pub5. PMID: 28981972 Free PMC article. Updated.
-
Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):379-389. doi: 10.5863/1551-6776-23.5.379. J Pediatr Pharmacol Ther. 2018. PMID: 30429692 Free PMC article.
-
Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing.Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3211-6. doi: 10.1007/s10096-012-1687-6. Epub 2012 Jul 12. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22790537
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical